Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2008

01.10.2008 | Hepatic and Pancreatic Tumors

Influence of Hepatic Resection Margin on Recurrence and Survival in Intrahepatic Cholangiocarcinoma

verfasst von: Dietmar Tamandl, MD, Beata Herberger, MSc, Birgit Gruenberger, MD, Harald Puhalla, MD, Markus Klinger, MD, Thomas Gruenberger, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Intrahepatic cholangiocarcinoma (ICC) is a rare disease in the Western world, hence little is known about its optimal surgical management. We analyzed whether hepatic resection margin is a prognostic factor for local or distant recurrence and survival in patients resected with curative intent.

Methods

Seventy-four patients underwent potentially curative surgery for ICC at our institution from 1994 to 2007. Demographic, and tumor- and surgery-related details including hepatic resection margin were recorded, patients were followed up for recurrence and survival. All patients were resected using modern dissection devices (CUSA® or Waterjet®).

Results

Fifty-nine patients (80%) underwent R0 resection, 15 (20%) had a resection margin greater than 10 mm (wide margin, WM) and 38 (51%) between 1 and 10 mm (close margin, CM). In 14 patients (19%), hepatic resection margin was involved on histological examination; perioperative mortalities were excluded from analysis (n = 7). Forty-seven patients developed recurrence (WM, CM, and R1): hepatic recurrence was observed in 40%, 58%, and 50% of patients; extrahepatic spread occurred in 27, 16, and 14%; and 33, 26, and 36% had no recurrence of disease so far (P = 0.755). There was no difference between groups regarding local versus disseminated hepatic recurrence. Median recurrence free survival was 11.4 months (WM), 9.8 months (CM), and 9.9 months (R1), respectively (P = 0.880). Median overall survival was 27.2 months (WM), 29.7 months (CM), and not reached in the R1 group, (P = 0.350).

Conclusion

Hepatic resection margin seems to play a minor role in the prognosis of ICC as long as complete tumor clearance can be achieved with a modern liver dissection technique.
Literatur
1.
Zurück zum Zitat Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003; 10:288–91PubMedCrossRef Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003; 10:288–91PubMedCrossRef
2.
Zurück zum Zitat Sano T, Shimada K, Sakamoto Y, et al. Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol 2008; 15:590–9PubMedCrossRef Sano T, Shimada K, Sakamoto Y, et al. Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol 2008; 15:590–9PubMedCrossRef
3.
Zurück zum Zitat Urahashi T, Yamamoto M, Ohtsubo T, et al. Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma. Hepatogastroenterology 2007; 54:346–9PubMed Urahashi T, Yamamoto M, Ohtsubo T, et al. Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma. Hepatogastroenterology 2007; 54:346–9PubMed
4.
Zurück zum Zitat Valverde A, Bonhomme N, Farges O, et al. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg 1999; 6:122–7PubMedCrossRef Valverde A, Bonhomme N, Farges O, et al. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg 1999; 6:122–7PubMedCrossRef
5.
Zurück zum Zitat Yeh CN, Jan YY, Chen MF. Hepatectomy for peripheral cholangiocarcinoma in elderly patients. Ann Surg Oncol 2006; 13:1553–9PubMedCrossRef Yeh CN, Jan YY, Chen MF. Hepatectomy for peripheral cholangiocarcinoma in elderly patients. Ann Surg Oncol 2006; 13:1553–9PubMedCrossRef
6.
Zurück zum Zitat Kim YT, Byun JS, Kim J, et al. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology 2003; 50:8–12PubMed Kim YT, Byun JS, Kim J, et al. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology 2003; 50:8–12PubMed
7.
Zurück zum Zitat Chen MF, Jan YY, Jeng LB, et al. Intrahepatic cholangiocarcinoma in Taiwan. J Hepatobiliary Pancreat Surg 1999; 6:136–41PubMedCrossRef Chen MF, Jan YY, Jeng LB, et al. Intrahepatic cholangiocarcinoma in Taiwan. J Hepatobiliary Pancreat Surg 1999; 6:136–41PubMedCrossRef
8.
Zurück zum Zitat Jan YY, Yeh CN, Yeh TS, et al. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 2005; 11:1779–84PubMed Jan YY, Yeh CN, Yeh TS, et al. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 2005; 11:1779–84PubMed
9.
Zurück zum Zitat Zhou YM, Yin ZF, Yang JM, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008; 14:632–5PubMedCrossRef Zhou YM, Yin ZF, Yang JM, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008; 14:632–5PubMedCrossRef
10.
Zurück zum Zitat Tan JC, Coburn NG, Baxter NN, et al. Surgical management of intrahepatic cholangiocarcinoma–a population-based study. Ann Surg Oncol 2008; 15:600–8PubMedCrossRef Tan JC, Coburn NG, Baxter NN, et al. Surgical management of intrahepatic cholangiocarcinoma–a population-based study. Ann Surg Oncol 2008; 15:600–8PubMedCrossRef
11.
Zurück zum Zitat Nathan H, Pawlik TM, Wolfgang CL, et al. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 2007; 11:1488–96; discussion 1496–7PubMedCrossRef Nathan H, Pawlik TM, Wolfgang CL, et al. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 2007; 11:1488–96; discussion 1496–7PubMedCrossRef
12.
Zurück zum Zitat Shimada K, Sano T, Sakamoto Y, et al. Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases. J Surg Oncol 2007; 96:160–5PubMedCrossRef Shimada K, Sano T, Sakamoto Y, et al. Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases. J Surg Oncol 2007; 96:160–5PubMedCrossRef
13.
Zurück zum Zitat Paik KY, Jung JC, Heo JS, et al. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 2008; 23:766–70PubMedCrossRef Paik KY, Jung JC, Heo JS, et al. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 2008; 23:766–70PubMedCrossRef
14.
Zurück zum Zitat Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008; 143:366–74PubMedCrossRef Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008; 143:366–74PubMedCrossRef
15.
Zurück zum Zitat Miwa S, Miyagawa S, Kobayashi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 2006; 41:893–900PubMedCrossRef Miwa S, Miyagawa S, Kobayashi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 2006; 41:893–900PubMedCrossRef
16.
Zurück zum Zitat Lang H, Sotiropoulos GC, Fruhauf NR, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005; 241:134–43PubMed Lang H, Sotiropoulos GC, Fruhauf NR, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005; 241:134–43PubMed
17.
Zurück zum Zitat Puhalla H, Schuell B, Pokorny H, et al. Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surg 2005; 189:173–7PubMedCrossRef Puhalla H, Schuell B, Pokorny H, et al. Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surg 2005; 189:173–7PubMedCrossRef
18.
Zurück zum Zitat Bodingbauer M, Tamandl D, Schmid K, et al. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg 2007; 94:1133–8PubMedCrossRef Bodingbauer M, Tamandl D, Schmid K, et al. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg 2007; 94:1133–8PubMedCrossRef
19.
Zurück zum Zitat Are C, Gonen M, Zazzali K, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 2007; 246:295–300PubMedCrossRef Are C, Gonen M, Zazzali K, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 2007; 246:295–300PubMedCrossRef
20.
Zurück zum Zitat Chiu CT, Chiang JM, Yeh TS, et al. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma-Are they just apples and oranges? Dig Liver Dis 2008, March 7; [Epub ahead of print] Chiu CT, Chiang JM, Yeh TS, et al. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma-Are they just apples and oranges? Dig Liver Dis 2008, March 7; [Epub ahead of print]
21.
Zurück zum Zitat Iyer RV, Gibbs J, Kuvshinoff B, et al. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 2007; 14:3202–9PubMedCrossRef Iyer RV, Gibbs J, Kuvshinoff B, et al. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 2007; 14:3202–9PubMedCrossRef
22.
Zurück zum Zitat Nanashima A, Sumida Y, Abo T, et al. Patient outcome and prognostic factors in intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology 2007; 54:2337–42PubMed Nanashima A, Sumida Y, Abo T, et al. Patient outcome and prognostic factors in intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology 2007; 54:2337–42PubMed
23.
Zurück zum Zitat Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005; 29:728–33PubMedCrossRef Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005; 29:728–33PubMedCrossRef
24.
Zurück zum Zitat Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001; 193:384–91PubMedCrossRef Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001; 193:384–91PubMedCrossRef
25.
Zurück zum Zitat Lieser MJ, Barry MK, Rowland C, et al. Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 1998; 5:41–7PubMedCrossRef Lieser MJ, Barry MK, Rowland C, et al. Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 1998; 5:41–7PubMedCrossRef
26.
Zurück zum Zitat Shimada K, Sano T, Sakamoto Y, et al. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 2007; 31:2016–22PubMedCrossRef Shimada K, Sano T, Sakamoto Y, et al. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 2007; 31:2016–22PubMedCrossRef
27.
Zurück zum Zitat Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002; 89:1525–31PubMedCrossRef Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002; 89:1525–31PubMedCrossRef
28.
Zurück zum Zitat DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245:755–62PubMedCrossRef DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245:755–62PubMedCrossRef
29.
Zurück zum Zitat Hernandez J, Cowgill SM, Al-Saadi S, et al. An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resection. Ann Surg Oncol 2008; 15:807–14PubMedCrossRef Hernandez J, Cowgill SM, Al-Saadi S, et al. An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resection. Ann Surg Oncol 2008; 15:807–14PubMedCrossRef
Metadaten
Titel
Influence of Hepatic Resection Margin on Recurrence and Survival in Intrahepatic Cholangiocarcinoma
verfasst von
Dietmar Tamandl, MD
Beata Herberger, MSc
Birgit Gruenberger, MD
Harald Puhalla, MD
Markus Klinger, MD
Thomas Gruenberger, MD
Publikationsdatum
01.10.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0081-1

Weitere Artikel der Ausgabe 10/2008

Annals of Surgical Oncology 10/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.